glp-1 drugs overview Market Overview: Agonists and the Obesity Market | Blog GLP-1 Drugs: Fighting Diabetes and

North American Congress of Clinical Toxicology 2011

Choose Jardiance if you have heart failure, chronic kidney disease, or established cardiovascular diseaseit reduces CV death by 38% (EMPA-REG trial) and costs approximately $629/month

Heres how HR and Finance Leaders can take control of soaring GLP-1 drug costs

Here is what makes this situation uniquely complicated

Seven drugs have currently been approved for the treatment of Type 2 diabetes mellitus, including short-acting agents like exenatide and lixisenatide, as well as long-acting injectable agents such as albiglutide, dulaglutide, liraglutide, and semaglutide. GLP-1s regulate lipid metabolism, reducing the effects of hyperlipidemia and helping to lower the risk for both chronic kidney disease (CKD) and diabetic kidney disease. They have also been shown to reduce oxidative stress, which includes stimulating glomerular filtration and reducing vasoconstriction, slowing the progression of CKD. Limited data from clinical trials have been published on the effects of GLP-1 receptor agonists in individuals with post-liver transplant diabetes mellitus (PTDM)

Overview of current and emerging GLP-1 receptor agonists